CURE’s prostate cancer page is an extensive resource of cancer information featuring the latest prostate cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on prostate cancer.
January 17th 2020
How providers communicate medical bills to payers and patients, mandated by the US Centers for Medicare & Medicaid Services, still did not help patients and health care professionals in understanding differences in cost.
January 5th 2020
Researchers found that combining family history and genetic risk scores to determine inherited risk for prostate cancer could personalize screening strategies for men.
January 3rd 2020
A modified citrus pectin, naturally found in the peel of citrus fruits, showed continued benefit among men with prostate cancer.
December 22nd 2019
Men with metastatic castration-sensitive prostate cancer will now have a fourth treatment option to consider.
December 17th 2019
The Food and Drug Administration approved Xtandi for the treatment of patients with metastatic castration-sensitive prostate cancer.
December 6th 2019
New research suggests men with infertility could face a 30% to 60% higher risk of prostate cancer.
November 27th 2019
Although one in nine men will receive a prostate cancer diagnosis in his lifetime, cutting-edge research has allowed more men to live longer or even be cured.
November 21st 2019
On this week’s episode of the CURE Talks Cancer podcast, we talk with Grammy-winning songwriter and vocal producer Kuk Harrell about what it’s like to be “on the other side” of his prostate cancer diagnosis, and how he’s using his platform to shine a light on the disease.
November 13th 2019
Following a prostate cancer diagnosis, one survivor ditches the ‘macho man’ attitude for a lighter approach to life.
November 7th 2019
In order to turn your prostate cancer into a couch potato and keep it from spreading, your best chance is not to be one yourself.
October 30th 2019
During the 2019 Prostate Cancer Consensus Conference, one expert discussed three clinical trials and the future of genetic testing in patients with the disease.
October 23rd 2019
We've got a sneak peek at what’s inside CURE®'s 2019 Genitourinary Cancers special issue.
October 20th 2019
Recent changes to the National Comprehensive Cancer Network (NCCN) guidelines around prostate cancer have updated the indications for genetic testing and have opened up a broader discussion on how it can be used to improve prostate cancer detection and treatment, according to Dr. James Mohler.
October 18th 2019
Active surveillance has become the treatment of choice for low-risk prostate cancer, but new tools are needed to make it more precise.
October 18th 2019
In the medical community, we know that, at a population level, active surveillance is better for certain men with prostate cancer, so we believe the benefit weighs in their favor. We would like to offer men more certainty that surveillance can work for them and hope that, in the next few years, research will bring that to pass.
October 7th 2019
Obese patients being treated for breast or prostate cancer showed higher levels of mental and physical distress than nonobese patients with these diseases, but the pattern did not hold true in those with colorectal cancer, according to a study.
October 6th 2019
A recent study found no different in disease recurrence among men with prostate cancer when they were given radiation after surgery or not.
October 3rd 2019
Phase 3 trial findings showed that treatment with Lynparza delayed disease progression by about four months compared with newer hormonal agents in pre-treated patients with metastatic castration-resistant prostate cancer and faulty DNA repair genes.
September 28th 2019
Morever, the next-generation androgen receptor improved overall survival, compared with placebo, in patients with nonmetastatic castration-resistant prostate cancer, according to updated findings of the phase 3 SPARTAN trial.
September 25th 2019
Here is a list of the recent trial initiations that occurred within the cancer space in September.
September 23rd 2019
For Prostate Cancer Awareness Month, here’s a round-up of the latest news and updates in this disease space.
September 21st 2019
Men with castration-sensitive prostate cancer now have an option for when treatment with androgen deprivation therapy alone is not enough.
September 18th 2019
A phase 3 trial showed a 33% reduction in the risk of death when patients were treated with Erleada compared with placebo.
September 3rd 2019
I encourage men to be more knowledgeable of their family history and to potentially begin testing for prostate cancer earlier if you have a family history of the disease.
August 27th 2019
Here is a list of the recent trial initiations that occurred within the cancer space in August.
August 1st 2019
Following the Food and Drug Administration’s approval of Nubeqa, men with non-metastatic castration-resistant prostate cancer now have an earlier more precise treatment option.
July 31st 2019
The Food and Drug Administration granted a priority review to Nubeqa for the treatment of men with non-metastatic castration-resistant prostate cancer.
July 19th 2019
From today’s top performers and athletes to surprising findings about prostate cancer treatment, here’s what is making headlines in the cancer space this week.
July 16th 2019
One patient and a physician expert discuss a variety of topics in prostate cancer.